Mines D`or Orbec Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 375
- Market Cap
- $121.4M
- Website
- http://www.bluebirdbio.com
- Introduction
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
CAR T-Cell Therapy Approved for Multiple Myeloma
CAR T-cell therapy, specifically idecabtagene vicleucel (Abecma), was FDA-approved for multiple myeloma patients unresponsive to prior treatments. In a study, 72% of participants saw tumor reduction, with remissions lasting a median of 11 months. Despite its effectiveness, the therapy can cause severe side effects and is costly, priced at $419,500 per infusion.
CAR-T Cell Therapy Market - Market Size, Forecasts, Trials
CAR-T cell therapy, a groundbreaking immunotherapy, modifies patient T-cells to target and destroy cancer cells, acting as 'living drugs.' With 11 products commercialized, including 7 FDA-approved, the therapy shows promise in treating blood cancers. Challenges include expanding to solid tumors, reducing 'vein-to-vein' time, and improving reimbursement. The industry is advancing through gene-transfer techniques, partnerships, and 'on-off' switches in CAR-T cells to enhance efficacy and safety.
© Copyright 2025. All Rights Reserved by MedPath